Atopic Dermatitis - Pipeline Review, H2 2015

Atopic Dermatitis - Pipeline Review, H2 2015

Code: GMDHC7206IDB | Published: Nov-2015 | Pages: 340 | Global Markets Direct
Price :

* Required Fields



This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Abeome Corporation
Almirall, S.A.
Amgen Inc.
Amorepacific Corporation
Anacor Pharmaceuticals, Inc.
AnaMar AB
AnaptysBio, Inc.
AnGes MG, Inc.
Aquinox Pharmaceuticals Inc.
Blueberry Therapeutics Ltd
Brickell Biotech, Inc.
Celgene Corporation
ChemoCentryx, Inc.
ChironWells GmbH
Chugai Pharmaceutical Co., Ltd.
Creabilis SA
Delenex Therapeutics AG
Dermira Inc.
Dr. August Wolff GmbH & Co. KG Arzneimittle
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Foamix Pharmaceuticals Ltd.
Fountain Biopharma Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Grupo Ferrer Internacional, S.A.
Han Wha Pharma Co., Ltd.
HanAll Biopharma Co., Ltd.
Herantis Pharma Plc
iCo Therapeutics Inc.
Immune Pharmaceuticals Inc.
Inflamalps SA
Japan Tobacco Inc.
Johnson & Johnson
LegoChem Biosciences, Inc
LEO Pharma A/S
Madam Therapeutics B.V.
MedImmune, LLC
Mitsubishi Tanabe Pharma Corporation
NeoPharm Co., Ltd.
Novartis AG
Nuvo Research Inc.
Otsuka Holdings Co., Ltd.
Oxagen Limited
Pfizer Inc.
Pharis Biotec GmbH
Pharmedartis GmbH
Provectus Biopharmaceuticals, Inc.
R-Tech Ueno, Ltd.
Regeneron Pharmaceuticals, Inc.
Signum Dermalogix, Inc
Spherium Biomed S.L.
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd.
Takeda Pharmaceutical Company Limited
Thesan Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Vicore Pharma AB
Vitae Pharmaceuticals, Inc.
VivaCell Biotechnology Espana S.L.
Welichem Biotech Inc.
Xencor, Inc.
Yungjin Pharm. Co., Ltd.
Ziarco Pharma Ltd

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients